The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine Nuvaxovid, developed by Novavax, the fifth COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is…
The EU and pharmaceutical company AstraZeneca have reached an agreement which will secure the delivery of the remaining COVID-19 vaccine doses to Member States under the terms of the Advance Purchase Agreement concluded on 27 August 2020 with AstraZeneca. The agreement will also end the pending litigation before the Brussels Court. Commissioner for Health and…
AstraZeneca issued a press release announcing that clinical trials for their coronavirus vaccine, AZD1222, under development resumed last week in the UK. The vaccine AZD1222 was co-invented by the University of Oxford and its spin-off company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus)…
The European Commission says it has concluded exploratory talks with CureVac to purchase a potential vaccine against COVID-19. This is following the positive steps with Sanofi-GSK on 31 July and Johnson and Johnson on 13 August and the signature of an Advance Purchase Agreement with AstraZeneca on 14 August. The envisaged contract with CureVac would…
